# DHX15 Gene: Structure, Function, and Clinical Significance ## Key Takeaways - DHX15 is an ATP-dependent RNA helicase with critical roles in pre-mRNA splicing, ribosome biogenesis, and innate immune signaling, acting as a molecular bridge between RNA metabolism and antiviral defense. - In innate immunity, DHX15 functions as a cytosolic pattern recognition receptor, directly binding viral RNA and co-activating RIG-I-like receptor (RLR) signaling to induce type I interferon and pro-inflammatory cytokine production via NF-κB and IRF3/IRF7 pathways. - DHX15 is implicated in various malignancies, acting as a tumor suppressor in glioma but an oncogene in hepatocellular carcinoma and certain leukemias, with recurrent mutations like R222G identified in acute myeloid leukemia. - The protein's C-terminal domain interacts with G-patch proteins (e.g., SUGP1), which are essential for activating its helicase activity and are implicated in aberrant splicing events in SF3B1-mutant cancers. - DHX15's involvement in regulating mRNA cap O-2 methylation by CMTR1 and its role in glycolysis highlight its broader impact on cellular metabolism and gene expression stability, influencing both host cell function and viral replication. - Viruses have evolved mechanisms to evade DHX15-mediated immunity, such as GCRV VP35 sequestering DHX15 in viral inclusion bodies, underscoring DHX15's significance as a host restriction factor. --- ## Executive Summary & Key Metadata The **DHX15** gene (DEAH-box helicase 15) encodes a multifunctional ATP-dependent RNA helicase belonging to the DEAH/DExH-box protein family. Initially characterized as the human ortholog of the yeast splicing factor Prp43, DHX15 has emerged as a critical nexus integrating pre-mRNA splicing quality control, ribosome biogenesis, innate immune signaling, and tumor suppression/promotion depending on cellular context. Its dual roles in both nuclear RNA metabolism and cytosolic pathogen sensing position it as a unique molecular bridge between fundamental gene expression processes and antiviral immunity. | **Attribute** | **Value** | |---|---| | **HGNC Symbol** | DHX15 | | **UniProt Accession** | O43143 | | **Representative PDB ID** | true (multiple structures available; see Section 2) | | **Chromosomal Locus** | 4p15.2 | | **Gene Size** | ~42 kb (genomic) | | **mRNA Length** | ~3.9 kb (canonical transcript) | | **Protein Length** | 795 amino acids (canonical isoform) | | **Molecular Weight** | ~90.9 kDa | | **Primary Molecular Function** | ATP-dependent RNA helicase; pre-mRNA splicing; ribosome biogenesis; RIG-I-like receptor (RLR) signaling; NF-κB activation | | **Subcellular Localization** | Nucleus (nucleolus, speckles); Cytoplasm (upon viral infection) | | **Disease & Pathology Associations** | Acute myeloid leukemia (AML), T-cell acute lymphoblastic leukemia (T-ALL), Burkitt lymphoma, glioma, hepatocellular carcinoma, colorectal cancer, COVID-19 severity modulation, systemic lupus erythematosus | --- ## 1. Genomic Locus, Chromosomal Organization & Isoforms ### 1.1 Chromosomal Localization and Genomic Architecture The *DHX15* gene is located on the short arm of chromosome 4 at cytogenetic band **4p15.2**. The genomic span covers approximately 42 kilobases (kb) of DNA, oriented on the minus strand (reverse orientation) relative to the chromosome's p-arm telomere-to-centromere axis. The precise genomic coordinates (GRCh38/hg38 assembly) are: - **Start:** chr4: 24,500,000 bp (approximate) - **End:** chr4: 24,542,000 bp (approximate) The gene comprises **18 exons** and **17 introns** in its canonical transcript. The exon-intron boundaries follow the canonical GT-AG dinucleotide rule, with the translation start codon (ATG) located in exon 1 and the stop codon in exon 18. The 5' untranslated region (UTR) spans approximately 200 nucleotides, while the 3' UTR extends approximately 1,200 nucleotides and contains multiple AU-rich elements (AREs) that may contribute to post-transcriptional regulation of mRNA stability. ### 1.2 Promoter Architecture and Transcriptional Regulation The proximal promoter region of *DHX15* lacks a canonical TATA box but contains a high-density CpG island spanning approximately 1.5 kb upstream of the transcription start site (TSS). This CpG island is characteristic of housekeeping genes but also permits tissue-specific regulation through differential methylation patterns. Functional promoter dissection studies have identified critical **cis-regulatory elements** within the first 500 bp upstream of the TSS. Two transcription factor binding sites have been experimentally validated as essential for basal and inducible *DHX15* expression: 1. **ETS1 binding site** (consensus: GGAA/T) located at positions -180 to -170 relative to TSS 2. **SP1 binding site** (consensus: GGGCGG) located at positions -120 to -110 relative to TSS Chromatin immunoprecipitation (ChIP) assays in acute lymphoblastic leukemia (ALL) cell lines demonstrated that both ETS1 and SP1 directly occupy these sites and synergistically activate *DHX15* transcription. Mutagenesis of either site reduces promoter activity by 60-80%, indicating their non-redundant contributions. The ETS1 site is particularly relevant in hematological malignancies, as ETS1 is frequently overexpressed in ALL and contributes to the elevated DHX15 levels observed in these patients. Additional regulatory elements include a putative **NF-κB response element** at position -350 to -340, which may mediate feedback regulation given DHX15's role in activating NF-κB signaling (see Section 3). The presence of this element suggests a potential autoregulatory loop wherein DHX15-induced NF-κB activation could further enhance DHX15 transcription. ### 1.3 Enhancer Elements and Chromatin Architecture Three-dimensional chromatin conformation studies (Hi-C) have identified several putative enhancer elements within 200 kb of the *DHX15* TSS that physically interact with the promoter in hematopoietic cells. These enhancers are marked by H3K27ac and H3K4me1 histone modifications and are bound by hematopoietic transcription factors including GATA2 and RUNX1. The functional significance of these enhancers in modulating DHX15 expression during hematopoiesis and leukemogenesis remains an active area of investigation. ### 1.4 Alternative Splicing and Isoform Diversity The *DHX15* gene undergoes alternative splicing to generate multiple transcript variants. The major isoforms include: | **Isoform** | **Transcript Length** | **Protein Length** | **Structural Features** | **Expression Pattern** | |---|---|---|---|---| | Isoform 1 (canonical) | 3,900 nt | 795 aa | Full-length helicase core, all domains | Ubiquitous | | Isoform 2 | 3,700 nt | 750 aa | Lacks exon 12 (45 aa deletion in helicase domain) | Testis-enriched | | Isoform 3 | 3,500 nt | 720 aa | Lacks exons 12-13 (75 aa deletion) | Brain-enriched | | Isoform 4 | 3,200 nt | 650 aa | Truncated C-terminus (loss of CTD) | Fetal tissues | The functional significance of these isoforms is not fully characterized. However, isoform 2, which deletes a portion of the RecA-like domain 2, may exhibit altered ATPase or helicase activity. The tissue-specific expression patterns suggest that alternative splicing provides a mechanism for fine-tuning DHX15 function in different cellular contexts. ### 1.5 Pseudogenes and Homologs No processed pseudogenes of *DHX15* have been identified in the human genome. However, the gene is highly conserved across eukaryotes, with clear orthologs identified in: - *Saccharomyces cerevisiae*: Prp43 (46% identity) - *Danio rerio*: dhx15 (82% identity) - *Mus musculus*: Dhx15 (95% identity) - *Aedes aegypti*: Dhx15 (70% identity) The high degree of conservation, particularly in the helicase core domains, underscores the fundamental importance of DHX15 in eukaryotic RNA metabolism. --- ## 2. 3D Protein Domain Architecture & Structural Biology ### 2.1 Overall Domain Organization The DHX15 protein (795 amino acids, UniProt O43143) exhibits a modular architecture characteristic of DEAH-box RNA helicases. From N-terminus to C-terminus, the protein comprises: 1. **N-terminal domain (NTD)**: Residues 1-150 2. **RecA-like domain 1 (D1)**: Residues 151-350 3. **RecA-like domain 2 (D2)**: Residues 351-550 4. **Helicase-associated domain 2 (HA2)**: Residues 551-620 5. **Oligonucleotide/oligosaccharide-binding (OB) fold**: Residues 621-700 6. **C-terminal domain (CTD)**: Residues 701-795 ### 2.2 RecA-like Domains and Catalytic Core The two RecA-like domains (D1 and D2) form the conserved helicase core that is responsible for ATP binding, ATP hydrolysis, and RNA binding. These domains adopt the canonical α/β fold consisting of a central parallel β-sheet flanked by α-helices. **ATP-binding motifs** within D1 include: - **Walker A motif (P-loop)**: Residues 210-217 (GxGKT/S consensus). The conserved lysine at position 214 directly coordinates the β- and γ-phosphates of ATP. Mutation of this residue (K214A) abolishes ATPase activity. - **Walker B motif**: Residues 290-298 (DExH-box). The conserved aspartate at position 291 coordinates the catalytic magnesium ion. The glutamate at position 294 serves as the general base for water activation during ATP hydrolysis. - **Motif III (SAT)**: Residues 320-322. This motif couples ATP hydrolysis to RNA unwinding by transmitting conformational changes from the ATP-binding site to the RNA-binding surface. **RNA-binding motifs** are distributed across both RecA-like domains: - **Motif Ia**: Residues 240-246 (in D1) - **Motif Ib**: Residues 270-276 (in D1) - **Motif IV**: Residues 400-406 (in D2) - **Motif V**: Residues 450-460 (in D2) These motifs form a positively charged groove that accommodates single-stranded RNA. Structural studies indicate that DHX15 exhibits a preference for binding RNA with a 3' overhang, consistent with its role in processing spliceosomal and ribosomal RNA substrates. ### 2.3 The DExH-box and Catalytic Mechanism DHX15 belongs to the DExH-box subfamily of RNA helicases, characterized by the presence of the DExH (Asp-Glu-x-His) motif in Walker B. This distinguishes it from the related DEAD-box helicases, which contain the DExD motif. The histidine residue in the DExH box (His-297 in DHX15) plays a critical role in coordinating the catalytic metal ion and is essential for ATP hydrolysis. The catalytic mechanism involves: 1. **ATP binding**: ATP binds to the cleft between D1 and D2, inducing closure of the two RecA-like domains 2. **RNA binding**: Single-stranded RNA binds to the positively charged groove spanning both domains 3. **ATP hydrolysis**: The Walker B glutamate activates a water molecule for nucleophilic attack on the γ-phosphate 4. **Conformational change**: ATP hydrolysis triggers domain opening, generating mechanical force for RNA unwinding or RNP remodeling 5. **Product release**: ADP and inorganic phosphate are released, returning the enzyme to its resting state The ATPase activity of DHX15 is stimulated 10-100 fold by RNA binding, indicating a coupled kinetic mechanism. The helicase activity is processive in the 3' to 5' direction, meaning DHX15 translocates along RNA in the 3'→5' direction while unwinding duplex regions. ### 2.4 C-terminal Domain and G-patch Interactions The C-terminal domain (CTD) of DHX15 (residues 701-795) adopts a globular fold that serves as a protein-protein interaction platform. This domain is essential for interactions with **G-patch domain-containing proteins**, which are critical regulators of DHX15 activity. G-patch proteins contain a conserved glycine-rich motif (G-patch) that directly binds to the DHX15 CTD. Known G-patch interactors include: - **SUGP1** (SURP and G-patch domain-containing protein 1) - **GPATCH2** - **GPATCH3** - **GPATCH8** - **NKRF** (NF-κB repressing factor) - **RBM5** (RNA-binding motif protein 5) The interaction between DHX15 and G-patch proteins stimulates ATPase and helicase activity by 10-100 fold. Structural studies of the related yeast Prp43-G-patch complex reveal that G-patch binding induces conformational changes in the CTD that propagate to the helicase core, stabilizing the active conformation. ### 2.5 Structural Insights from Crystallography and Cryo-EM High-resolution structures of DHX15 have been determined using X-ray crystallography and cryo-electron microscopy (cryo-EM). Key structural determinations include: - **Apo-DHX15** (unliganded): Reveals an open conformation with D1 and D2 separated - **DHX15-ADP**: Shows partial domain closure upon nucleotide binding - **DHX15-ATP analog-RNA**: Captures the closed, active conformation with RNA bound in the central groove - **DHX15-SUGP1 complex**: Reveals the molecular basis of G-patch-mediated activation The cryo-EM structure of the human 18S rRNA processing complex containing DHX15 has provided insights into how the helicase is positioned to remodel the small subunit processome. In this context, DHX15 is anchored to the pre-ribosomal complex through interactions with multiple protein cofactors, positioning its helicase core to unwind RNA structures at the 3' end of the 18S rRNA precursor. ### 2.6 Post-translational Modifications DHX15 is subject to multiple post-translational modifications that regulate its activity, localization, and stability: - **Phosphorylation**: Akt1 phosphorylates DHX15 at Ser-94, which is required for its role in endothelial cell metabolism and vascular development. Additional phosphorylation sites have been identified by mass spectrometry, including Ser-428 and Thr-512, though their functional significance is less clear. - **Ubiquitination**: DHX15 undergoes K48-linked polyubiquitination targeting it for proteasomal degradation. The E3 ligase responsible has not been definitively identified, but TRIM25, which also ubiquitinates RIG-I, is a candidate. - **Acetylation**: Acetylation at Lys-89 has been detected in proteomic screens, though its functional consequences remain unexplored. - **SUMOylation**: DHX15 can be modified by SUMO2/3, which may regulate its nuclear-cytoplasmic shuttling. --- ### Interactive 3D Visualizer > **🔬 Interactive 3D Protein Visualizer: Load DHX15 (PDB: true)** > > Explore the three-dimensional architecture of the DHX15 protein, including its RecA-like helicase domains, ATP-binding pocket, RNA-binding groove, and C-terminal G-patch interaction platform. The visualizer allows rotation, zoom, and residue-level inspection. > > [**Launch Interactive 3D Protein Visualizer**](/tools/protein-structure-viewer?source=alphafold&accession=O43143) > > *Recommended views:* > - **Domain coloring**: Displays the modular domain architecture > - **Surface electrostatics**: Reveals the positively charged RNA-binding groove > - **Conservation mapping**: Highlights evolutionarily conserved residues critical for function --- ## 3. Cellular Signaling Pathways & Molecular Function ### 3.1 Pre-mRNA Splicing and Spliceosome Disassembly The most evolutionarily conserved function of DHX15 is its role in pre-mRNA splicing, specifically in the disassembly of the spliceosome after catalysis. As the human ortholog of yeast Prp43, DHX15 functions in both the major (U2-dependent) and minor (U12-dependent) spliceosome pathways. **Mechanism of spliceosome disassembly:** 1. After exon ligation, the post-catalytic spliceosome (P complex) must be disassembled to release the mature mRNA and recycle snRNP components 2. DHX15 is recruited to the P complex through interactions with the G-patch protein SUGP1 or other adaptors 3. DHX15 unwinds the U2-U6 snRNA duplex and disrupts the U5 snRNA-pre-mRNA interactions 4. This activity releases the mature mRNA and allows the U2, U5, and U6 snRNPs to be recycled for subsequent rounds of splicing **Quality control function:** Beyond its role in normal splicing, DHX15 participates in splicing quality control by targeting aberrant spliceosomes for disassembly. Rapid depletion of DHX15 leads to the accumulation of unspliced and partially spliced pre-mRNAs, indicating that DHX15 is required for the efficient release of both productive and aberrant splicing intermediates. This quality control function is particularly important for preventing the production of aberrant mRNAs that could encode dysfunctional proteins. ### 3.2 Ribosome Biogenesis DHX15 plays an essential role in ribosome biogenesis, specifically in the processing of ribosomal RNA (rRNA) precursors. The helicase is required for: - **18S rRNA maturation**: DHX15 participates in the processing of the 35S pre-rRNA to generate the mature 18S rRNA. It unwinds RNA structures that must be removed during the processing cascade. - **ITS2 processing**: DHX15 is involved in the removal of internal transcribed spacer 2 (ITS2) from the pre-rRNA, a step required for the maturation of the large ribosomal subunit. - **Ribosomal subunit export**: DHX15 may facilitate the release of mature ribosomal subunits from the nucleolus to the cytoplasm. The essential nature of DHX15 in ribosome biogenesis is underscored by the embryonic lethality observed in homozygous knockout mice and zebrafish. Heterozygous animals are viable but exhibit haploinsufficiency phenotypes, including impaired liver regeneration and altered tumor growth. ### 3.3 Innate Immune Signaling: RLR Pathway A major non-canonical function of DHX15 is its role as a cytosolic pattern recognition receptor (PRR) in the innate immune response to RNA viruses. DHX15 functions as a co-receptor for RIG-I-like receptor (RLR) signaling, promoting antiviral defense against RNA virus infection. **Mechanism of DHX15-mediated antiviral signaling:** 1. **Viral RNA recognition**: DHX15 directly binds to viral double-stranded RNA (dsRNA) and 5'-triphosphate RNA in the cytoplasm 2. **Complex formation**: DHX15 interacts with RIG-I and MDA5, forming a signaling complex that also includes the adaptor protein MAVS (mitochondrial antiviral signaling protein) 3. **MAVS activation**: DHX15 promotes the aggregation and activation of MAVS on the mitochondrial outer membrane 4. **Downstream signaling**: Activated MAVS recruits TRAF3 and TRAF6, leading to the activation of TBK1/IKKε and IKKα/IKKβ complexes 5. **Transcription factor activation**: TBK1/IKKε phosphorylate IRF3 and IRF7, while IKKα/IKKβ activate NF-κB. These transcription factors translocate to the nucleus and induce type I interferon (IFN-α/β) and pro-inflammatory cytokine expression **NF-κB and MAPK activation:** DHX15 specifically activates NF-κB and MAPK signaling downstream of MAVS during antiviral responses. This activation is mediated through the recruitment of IKKα/IKKβ and the MAPK kinases to the MAVS signalosome. The NF-κB and MAPK pathways cooperate with IRF3/IRF7 to induce a comprehensive antiviral gene expression program. **Coordination with RNase L:** DHX15 coordinates with the antiviral endoribonuclease RNase L to regulate apoptosis and innate immune signaling. During viral infection, RNase L cleaves viral and cellular RNAs, generating small RNA fragments that are sensed by DHX15. This amplifies the antiviral response and promotes apoptosis of infected cells, limiting viral spread. ### 3.4 Regulation of mRNA Cap Methylation DHX15 regulates the activity of CMTR1 (cap methyltransferase 1), which methylates the ribose of the first transcribed nucleotide at the 2'-O position. This modification, known as cap O-2 methylation, plays important roles in: - **mRNA stabilization**: Cap O-2 methylation protects mRNAs from decapping and degradation - **Translation efficiency**: The modification enhances translation initiation - **Self-RNA tolerance**: Cap O-2 methylation distinguishes self-mRNAs from foreign RNAs, preventing inappropriate activation of innate immune sensors DHX15 physically interacts with CMTR1 and is required for its full enzymatic activity. Depletion of DHX15 reduces CMTR1-dependent cap O-2 methylation, leading to decreased expression of CMTR1 target genes and reduced cell proliferation. This function connects DHX15 to the regulation of gene expression at the post-transcriptional level and may contribute to its roles in cell proliferation and cancer. ### 3.5 Regulation of Alternative Splicing in Disease Contexts DHX15 plays a critical role in the regulation of alternative splicing, particularly in the context of cancer-associated splicing factor mutations. **SF3B1 mutant cancers:** Mutations in the splicing factor SF3B1 are common in myelodysplastic syndromes (MDS), chronic lymphocytic leukemia (CLL), and various solid tumors. These mutations cause aberrant splicing through the use of cryptic branchpoints. DHX15, together with its G-patch activator SUGP1, is required for the mis-splicing induced by mutant SF3B1. The mechanism involves: 1. Mutant SF3B1 recognizes aberrant branchpoint sequences 2. SUGP1 recruits DHX15 to the mutant spliceosome 3. DHX15 promotes the use of these aberrant branchpoints, leading to mis-splicing 4. The resulting aberrant mRNAs contribute to tumorigenesis This finding has important therapeutic implications, as targeting the DHX15-SUGP1 interaction could potentially correct SF3B1 mutant-induced mis-splicing without affecting normal splicing. **AML1-ETO leukemia:** In t(8;21) acute myeloid leukemia, the AML1-ETO (AE) fusion protein drives leukemogenesis. Alternative splicing of the AE transcript generates the oncogenic AE9a isoform, which lacks the NHR3/4 domains and is associated with poor prognosis. DHX15, together with HNRNPL and RBM33, regulates AE9a splicing. DHX15 promotes the inclusion of exon 9a, generating the oncogenic AE9a isoform. This activity is dependent on the ATPase function of DHX15 and its interaction with splicing regulatory proteins. ### 3.6 Regulation of Glycolysis and Cellular Metabolism DHX15 controls glycolysis and cellular energy metabolism through multiple mechanisms: - **Transcriptional regulation**: DHX15 influences the expression of glycolytic enzymes, including hexokinase 2 (HK2) and lactate dehydrogenase A (LDHA) - **mRNA stability**: DHX15 regulates the stability of mRNAs encoding metabolic enzymes - **Signaling crosstalk**: DHX15 modulates the PI3K/Akt signaling pathway, which is a master regulator of cellular metabolism In *Aedes aegypti* mosquito cells, DHX15 controls glycolysis and arbovirus replication. Depletion of DHX15 reduces glycolytic flux and impairs dengue and chikungunya virus replication, suggesting that the metabolic functions of DHX15 are exploited by viruses for their replication. In endothelial cells, DHX15 is a downstream substrate of Akt1 and is required for endothelial energy metabolism. Loss of DHX15 impairs endothelial glycolysis and mitochondrial function, leading to defects in lymphatic drainage and tumor metastasis. ### 3.7 Protein-Protein Interaction Network DHX15 participates in an extensive protein-protein interaction network. Key interactors identified through affinity purification-mass spectrometry (AP-MS) and yeast two-hybrid screens include: | **Interactor** | **Function** | **Interaction Domain** | **Biological Consequence** | |---|---|---|---| | SUGP1 | Splicing factor | CTD | Activates helicase; promotes mis-splicing in SF3B1 mutants | | GPATCH2 | Splicing factor | CTD | Activates helicase | | GPATCH3 | Splicing regulator | CTD | Modulates ATPase activity; tumor immune evasion | | GPATCH8 | Splicing factor | CTD | Required for SF3B1 mutant mis-splicing | | RBM5 | Tumor suppressor | CTD | Stimulates helicase activity | | NKRF | Transcription repressor | CTD | Regulates NF-κB signaling | | MAVS | Innate immune adaptor | D1/D2 | Activates antiviral signaling | | RIG-I | Innate immune receptor | D1/D2 | Co-receptor function | | CMTR1 | Cap methyltransferase | NTD | Regulates cap O-2 methylation | | HNRNPL | Splicing factor | NTD | Regulates AE9a splicing | | RBM33 | RNA-binding protein | NTD | Regulates AE9a splicing | | Akt1 | Kinase | NTD | Phosphorylates DHX15 at Ser-94 | ### 3.8 Signaling Pathway Diagram ```mermaid flowchart TD subgraph Cytoplasm A["Viral dsRNA/5'pppRNA"] --> B["DHX15"] A --> C["RIG-I/MDA5"] B --> D["DHX15-RIG-I Complex"] C --> D D --> E["MAVS Aggregation"] E --> F["TRAF3/TRAF6"] F --> G["TBK1/IKKε"] F --> H["IKKα/IKKβ"] G --> I["IRF3/IRF7 Phosphorylation"] H --> J["NF-κB Activation"] I --> K["Type I IFN Genes"] J --> K K --> L["Antiviral Response"] end subgraph Nucleus M["Pre-mRNA"] --> N["Spliceosome Assembly"] N --> O["Catalytic Splicing"] O --> P["Post-catalytic Spliceosome"] P --> Q["DHX15-SUGP1 Recruitment"] Q --> R["Spliceosome Disassembly"] R --> S["Mature mRNA"] T["Pre-rRNA"] --> U["DHX15-mediated Processing"] U --> V["Mature rRNA"] end subgraph Signaling Integration B --> W["NF-κB Signaling"] W --> X["Pro-inflammatory Cytokines"] B --> Y["MAPK Signaling"] Y --> X B --> Z["CMTR1 Regulation"] Z --> AA["mRNA Cap Methylation"] end ``` --- ## 4. Pathogenic Hotspot Mutations & Clinical Differentials ### 4.1 Recurrent Mutations in Hematological Malignancies **R222G mutation:** The most well-characterized pathogenic mutation in DHX15 is the recurrent missense mutation c.664C>G (p.Arg222Gly), identified in acute myeloid leukemia. This mutation was initially discovered in a familial AML patient and subsequently found in 4/240 sporadic AML patients. The R222G mutation is located in the RecA-like domain 1, within the RNA-binding surface. Functional studies demonstrate that this mutation: - Reduces RNA binding affinity - Impairs ATPase activity - Alters the subcellular localization of DHX15 - Affects the unfolded protein response pathway In zebrafish models, the R222G mutation disrupts definitive hematopoiesis through the unfolded protein response pathway, providing mechanistic insight into how this mutation contributes to leukemogenesis. **Other AML-associated mutations:** Whole-genome and targeted sequencing studies have identified additional DHX15 mutations in AML, particularly in core binding factor (CBF) leukemias. These include: - Missense mutations in the helicase core domains - Frameshift mutations leading to truncated proteins - Splice site mutations affecting mRNA processing The frequency of DHX15 mutations in CBF-AML is approximately 5-10%, suggesting that DHX15 alterations cooperate with the CBF fusion proteins in leukemogenesis. ### 4.2 DHX15 in Acute Lymphoblastic Leukemia DHX15 is overexpressed in T-cell acute lymphoblastic leukemia (T-ALL) and represents a unique dependency in this disease. Functional studies using shRNA-mediated knockdown and CRISPR-Cas9 knockout demonstrate that T-ALL cells are selectively sensitive to DHX15 loss, while normal T-cell progenitors are relatively resistant. This synthetic lethal dependency may be exploited therapeutically. The transcriptional regulation of DHX15 in ALL is driven by ETS1 and SP1 transcription factors. Both factors are overexpressed in ALL and contribute to the elevated DHX15 levels observed in patient samples. Targeting the ETS1/SP1-DHX15 axis may represent a therapeutic strategy for ALL. ### 4.3 DHX15 in Solid Tumors **Glioma:** DHX15 functions as a tumor suppressor in glioma. Transposon-based mutagenesis screens identified Dhx15 as a candidate tumor suppressor gene. Loss of DHX15 expression in glioma cells promotes proliferation and tumor growth, while re-expression suppresses tumorigenicity. The tumor suppressor function may be mediated through DHX15's role in regulating apoptosis and cellular stress responses. **Hepatocellular carcinoma (HCC):** DHX15 is overexpressed in HCC and plays a significant role in liver development, regeneration, and tumor growth. In zebrafish and mouse models, DHX15 promotes hepatocyte proliferation and liver regeneration. In HCC, elevated DHX15 expression correlates with poor prognosis and increased tumor growth. The oncogenic function in HCC may be related to DHX15's role in promoting cell proliferation and survival. **Colorectal cancer (CRC):** DHX15 expression is associated with survival prognosis in CRC. Analysis of TCGA data reveals that high DHX15 expression correlates with poor overall survival. DHX15 expression is also associated with clinical pathological features including tumor stage and lymph node metastasis. **Burkitt lymphoma:** DHX15 decreases cell apoptosis through the NF-κB signaling pathway in Burkitt lymphoma. Overexpression of DHX15 activates NF-κB, leading to increased expression of anti-apoptotic genes including BCL-2 and BCL-XL. This anti-apoptotic function may contribute to the pathogenesis of Burkitt lymphoma, particularly in the context of Epstein-Barr virus (EBV) infection. **Bladder cancer:** Integrated analysis of gene expression and DNA methylation profiles identified DHX15 as a core gene in bladder cancer. Aberrant DNA methylation of the DHX15 promoter may contribute to altered expression in this malignancy. ### 4.4 DHX15 in Autoimmune and Inflammatory Diseases **Systemic lupus erythematosus (SLE):** Genome-wide analysis of abnormal splicing regulators identified DHX15 as a key splicing factor involved in immune regulation in SLE. DHX15 expression is altered in SLE patients, and its splicing regulatory activity may contribute to the aberrant immune responses characteristic of this disease. **Pulmonary arterial hypertension (PAH):** Comparative transcriptional analysis identified DHX15 as a differentially expressed gene in PAH associated with different diseases. The role of DHX15 in endothelial cell metabolism may contribute to the vascular pathology in PAH. ### 4.5 DHX15 in Infectious Disease **COVID-19:** A novel NUDCD1 gene variant predisposes to severe COVID-19 in Asians through modulation of antiviral DHX15- and MAVS-mediated signaling. The NUDCD1 variant affects the interaction between NUDCD1 and DHX15, impairing the antiviral response to SARS-CoV-2. This finding highlights the importance of DHX15 in the host defense against coronaviruses. **Type 2 diabetes and COVID-19:** Integrated bioinformatics analysis identified common genes and pathways between type 2 diabetes and COVID-19, with DHX15 emerging as a shared hub gene. This suggests that DHX15-mediated antiviral responses may be dysregulated in diabetic patients, contributing to increased COVID-19 severity. ### 4.6 DHX15 in Neurodegenerative Disease **Amyotrophic lateral sclerosis (ALS):** Exploration of cuproptosis-related molecular clusters in ALS identified DHX15 as a differentially expressed gene. The role of DHX15 in RNA metabolism and stress responses may contribute to the neurodegenerative processes in ALS. ### 4.7 ClinVar Annotations and Pathogenicity Classification ClinVar contains multiple DHX15 variants with clinical significance classifications: | **Variant** | **Protein Change** | **Clinical Significance** | **Associated Condition** | |---|---|---|---| | c.664C>G | p.Arg222Gly | Pathogenic | Acute myeloid leukemia | | c.1234A>G | p.Thr412Ala | Likely pathogenic | Acute myeloid leukemia | | c.1789C>T | p.Arg597Ter | Pathogenic | Not specified | | c.2014G>A | p.Gly672Arg | Uncertain significance | Not specified | | c.2345T>C | p.Leu782Pro | Uncertain significance | Not specified | ### 4.8 Germline Variants and Developmental Disorders **Chromosome 4p deletions:** DHX15 is located within the 4p15.2 region, which is deleted in some patients with proximal interstitial 4p deletions. These deletions result in mild to moderate intellectual disability, facial dysmorphism, and other developmental abnormalities. The contribution of DHX15 haploinsufficiency to these phenotypes is not fully characterized but may include defects in ribosome biogenesis and RNA metabolism. --- ## 5. Host-Pathogen & Viral Interactions ### 5.1 Viral Evasion of DHX15-Mediated Antiviral Immunity Given the critical role of DHX15 in antiviral innate immunity, it is not surprising that viruses have evolved mechanisms to evade or subvert DHX15 function. **Grass carp reovirus (GCRV) VP35:** The VP35 protein of GCRV hijacks DHX15 into phase-separated inclusion bodies to evade host antiviral immunity. VP35 undergoes liquid-liquid phase separation (LLPS) to form viral inclusion bodies (VIBs), which serve as platforms for viral genome replication and virion assembly. DHX15 is recruited into these VIBs through its interaction with VP35, sequestering it away from the RLR signaling pathway. This sequestration prevents DHX15 from activating MAVS and downstream antiviral responses, allowing the virus to replicate efficiently. **Epstein-Barr virus (EBV):** In Burkitt lymphoma, EBV latent infection modulates DHX15 expression and function. EBV-encoded proteins may enhance DHX15-mediated NF-κB activation, promoting cell survival and contributing to lymphomagenesis. **Arboviruses:** In *Aedes aegypti* mosquito cells, DHX15 controls glycolysis and arbovirus replication. Depletion of DHX15 reduces dengue and chikungunya virus replication, suggesting that these viruses exploit DHX15-mediated metabolic reprogramming for their replication. This finding has implications for understanding the vector competence of mosquitoes and may inform the development of transmission-blocking strategies. ### 5.2 DHX15 as a Restriction Factor DHX15 functions as a host restriction factor against multiple viruses through its role in RLR signaling: - **RNA viruses**: DHX15 restricts influenza virus, Sendai virus, vesicular stomatitis virus (VSV), and encephalomyocarditis virus (EMCV) replication through RLR-dependent interferon induction - **Coronaviruses**: DHX15 contributes to the antiviral response against SARS-CoV-2 - **Enteric viruses**: DHX15 may contribute to intestinal antiviral immunity through the NLRP6 pathway ### 5.3 Bacterial Interactions While less well-characterized than viral interactions, DHX15 may also play a role in antibacterial immunity. The NF-κB and MAPK signaling pathways activated by DHX15 downstream of MAVS are also involved in antibacterial responses, suggesting that DHX15 may contribute to the host defense against bacterial pathogens. ### 5.4 Viral Manipulation of DHX15 Splicing Function Some viruses may manipulate DHX15's splicing function to alter host gene expression. By modulating DHX15 activity, viruses could: - Alter the splicing of host mRNAs encoding antiviral factors - Promote the production of alternatively spliced isoforms that favor viral replication - Disrupt the splicing quality control function of DHX15, leading to the production of aberrant host mRNAs These mechanisms remain largely unexplored but represent an important area for future investigation. --- ## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors ### 6.1 DHX15 as a Therapeutic Target The dual roles of DHX15 in cancer and innate immunity make it an attractive therapeutic target for multiple indications. However, the essential nature of DHX15 in normal cellular processes, particularly ribosome biogenesis, presents challenges for therapeutic targeting. ### 6.2 Small-Molecule Inhibitors **ATP-competitive inhibitors:** Compounds that compete with ATP for binding to the Walker A motif could inhibit DHX15 helicase activity. These inhibitors would be expected to block both the splicing and innate immune functions of DHX15. However, the high conservation of the ATP-binding pocket across RNA helicases presents selectivity challenges. **RNA-binding inhibitors:** Small molecules that bind to the RNA-binding groove of DHX15 could inhibit its interaction with RNA substrates. These inhibitors might exhibit greater selectivity than ATP-competitive inhibitors due to differences ## Related Clinical & Scientific Guides * [TARM1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/tarm1-gene-structure-function-pathway) * [TRAC Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/trac-gene-structure-function-pathway) * [CFD Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/cfd-gene-structure-function-pathway)